Stock IOVA IOVANCE BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Iovance Biotherapeutics, Inc.

Equities

IOVA

US4622601007

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-03 pm EDT 		5-day change 1st Jan Change
13.63 USD +5.82% Intraday chart for Iovance Biotherapeutics, Inc. +17.10% +67.65%
Mar. 29 General (Ret.) Merrill A. McPeak, Member of the Board of Directors of Iovance Biotherapeutics, Inc. Retires and Not Stands for Re-Election CI
Mar. 14 Piper Sandler Adjusts Iovance Biotherapeutics Price Target to $19 From $18, Maintains Overweight Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024
AQ
Iovance Biotherapeutics to Present at Upcoming Conferences
AQ
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4) - April 19, 2024
AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4)
AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
AQ
Iovance Biotherapeutics to Present at Upcoming Conferences
AQ
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
AQ
Iovance Biotherapeutics to Present at Upcoming Conferences
AQ
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
AQ
Iovance Biotherapeutics: Q4 Earnings Snapshot
AQ
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates 
AQ
Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024
AQ
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI for Advanced Melanoma
AQ
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI(TM) (lifileucel) for Advanced Melanoma
AQ
Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock
AQ
Novel immunotherapy approved for melanoma
AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
AQ
Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IOVA Stock
  4. News Iovance Biotherapeutics, Inc.
  5. Press Releases